article thumbnail

Daewoong Pharmaceutical revolutionizes drug development with AI-Driven DAISY system

Digital Health Global

Daewoong Pharmaceutical , a prominent player in the South Korean pharmaceutical industry, has unveiled its groundbreaking drug development system, Daewoong AI System (DAISY). Daewoong aims to leverage AI technology to reduce the drug development period to seven years and costs to approximately 600 billion won ($450 million).

article thumbnail

Pfizer, Tempus collaborate on cancer drug development

Mobi Health News

The multinational pharma company will access Tempus' AI-enabled data library to further therapeutic development and advance its portfolio in oncology.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New Flagship Pioneering drug development company exits stealth mode

Mobi Health News

Valo Health’s Opal Computational Platform uses machine learning, cloud computing and real-world data to assist in the drug discovery and development process.

article thumbnail

Infographic: Digital Measures in Oncology Drug Development

ActiGraph

Oncology is one of the most active and fastest growing areas of drug development research, outpacing other therapeutic areas in terms of study volume, complexity, cost, and duration.

article thumbnail

Infographic: Digital Measures in Oncology Drug Development

ActiGraph

Oncology is one of the most active and fastest growing areas of drug development research, outpacing other therapeutic areas in terms of study volume, complexity, cost, and duration.

article thumbnail

Koneksa Announces Study with New York Proton Center to Collect Patient-Generated Health Data During Proton Radiotherapy in Lung Cancer

Digital Health Global

By combining NYPC’s expertise in proton beam radiotherapy with Koneksa’s advanced remote monitoring solutions, the results from this study will advance our understanding of how patient-generated health data can improve radiotherapy treatment protocols in lung cancer.” The study, led by principal investigator Nitin Ohri, M.D.,

article thumbnail

Biofourmis announces major agreements with top pharmaceutical companies

Digital Health Global

Centered on digital biomarker and safety monitoring algorithm development, with a specific emphasis on cytokine release syndrome (CRS) detection, the oncology programs harness cutting-edge data science and technology to elevate remote data collection, patient monitoring, and safety protocols.